You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Ovarian cancer using novel nanoparticle formulations
SBC: KIROMIC BIOPHARMA INC Topic: 102DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Optimized lactoferrin for treatment of intracerebral hemorrhage
SBC: Pharmareview Corporation Topic: NINDSDESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Uniform, High Intensity X-ray Source for Blood Irradiation
SBC: National Nanomaterials, Inc Topic: 22aThere is an ongoing effort to replace high activity radioactive sources that could pose a risk for use as terrorist weapons with non-radioisotope based technologies. Currently radioactive sources serve a number of critical needs including the treatment and diagnosis of disease, inspection and certification of critical mechanical structures, the sterilization of food and medical products, ...
STTR Phase I 2014 Department of Energy -
Next Generation Semiconductor-Based Radiation Detectors Using Cadmium Magnesium Telluride
SBC: BRIMROSE TECHNOLOGY CORP Topic: 23cAt present, CdZnTe is considered the material of choice for efficient, room temperature gamma-radiation detection systems used for the detection and identification of radionuclides. Despite the advances in CdZnTe materials technology during the last decade, the major impediments in the progress of - ray detection technology are the low yield of device quality materials and detectors, and the limit ...
STTR Phase I 2014 Department of Energy -
Optical Waveguide Cross-Correlator for Attosecond Timing Synchronization
SBC: ADVR, INC. Topic: 32cThis Phase I SBIR/STTR will establish the feasibility of developing a precision balanced optical cross-correlator using engineered nonlinear optical waveguides. The proposed device will be important for future advances at large scale accelerator facilities by providing a means to achieve long-term sub- femtosecond timing and synchronization of all of a facilitys optical and RF sub-systems over fib ...
STTR Phase I 2014 Department of Energy -
Virtual Impact Sizing for Precursor Powders of Nb3Sn and Bi-2212 Superconductors
SBC: Accelerator Technology Corporation Topic: N/A65438 Large particles must be efficiently removed from powders used to fabricate superconducting wire. The presence of even a trace amount of large particles can ruin the superconducting properties of a large batch of wire, and limit the performance of all wire made with the powder-in-tube process. This project will apply an aerosol sorting technology to remove this limitation to supercon ...
STTR Phase I 2002 Department of Energy -
NON-NATURAL AMINO ACIDS IN PEPTIDE DRUG DEVELOPMENT
SBC: ARGOLYN BIOSCIENCE, INC. Topic: N/AArgolyn Bioscience Inc. is an early stage biotechnology company that creates novel peptide drugs and diagnostics with greatly improved intrinsic pharmaceutical properties through substitution of non-natural amino acid analogues for arginine (Arg) or lysine (Lys). In proof-of concept studies thus far, application of the Argolyn technology to peptides of therapeutic interest has resulted in dramatic ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
NOVEL NEUROTENSIN ANALOGS AS ANTISCHIZOPRENICS
SBC: ARGOLYN BIOSCIENCE, INC. Topic: N/ADESCRIPTION (provided by applicant): The brain peptide neurotensin (NT) and its active derivative NT [8-13] function as endogenous neuroleptics. Stable NT derivatives that cross the blood brain barrier therefore have significant potential for development as a new class of non-dopamineric antipsychotics expected not to display the adverse side effects associated with the dopaminergics. The best lit ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
ANTIMICROBIAL COATING FOR BIOFILM INHIBITION
SBC: Biomedical Development Corporation Topic: N/ADescription(provided by applicant): Candida is the third leading cause of catheter-related nosocomial bloodstream infections. Indwelling devices have been shown to support colonization and biofilm formulation by Candida. Intravenous lines are the most frequent indwelling device and are the single most common cause of candidemia. Once a Candida biofilm forms in vivo, removal of the substrate that i ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health